Humacyte (NASDAQ:HUMA) Shares Down 5.1% – What’s Next?

Humacyte, Inc. (NASDAQ:HUMA)’s stock price fell 5.1% during trading on Monday . The stock traded as low as $4.26 and last traded at $4.26. 1,752,903 shares changed hands during mid-day trading, a decline of 27% from the average session volume of 2,411,848 shares. The stock had previously closed at $4.49.

Analysts Set New Price Targets

A number of analysts have weighed in on HUMA shares. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 target price on shares of Humacyte in a research note on Thursday. BTIG Research reaffirmed a “buy” rating and issued a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 price target on shares of Humacyte in a research note on Friday, September 20th. Piper Sandler set a $6.00 price objective on Humacyte and gave the company a “neutral” rating in a research note on Friday, October 18th. Finally, EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $13.00.

Humacyte Price Performance

The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10. The company has a fifty day moving average of $5.31 and a 200 day moving average of $6.19. The firm has a market capitalization of $538.68 million, a P/E ratio of -3.35 and a beta of 1.47.

Insider Transactions at Humacyte

In related news, CEO Laura E. Niklason sold 811,172 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $4.44, for a total transaction of $3,601,603.68. Following the completion of the sale, the chief executive officer now owns 2,419,712 shares of the company’s stock, valued at $10,743,521.28. This trade represents a 25.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Kathleen Sebelius sold 5,182 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total value of $27,982.80. Following the completion of the transaction, the director now directly owns 40,276 shares in the company, valued at approximately $217,490.40. This trade represents a 11.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,584,153 shares of company stock worth $13,476,796 over the last three months. 11.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Humacyte

A number of large investors have recently bought and sold shares of the stock. nVerses Capital LLC acquired a new stake in shares of Humacyte in the 2nd quarter valued at about $28,000. Concurrent Investment Advisors LLC acquired a new position in Humacyte during the 3rd quarter worth approximately $75,000. Principal Financial Group Inc. bought a new position in Humacyte in the second quarter worth approximately $83,000. FORA Capital LLC acquired a new stake in Humacyte in the third quarter valued at approximately $96,000. Finally, Profund Advisors LLC bought a new stake in shares of Humacyte during the second quarter valued at approximately $97,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.